QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and fore
Express News | Qiagen NV : Morgan Stanley Cuts Target Price to $47 From $51
QIAGEN N.V. to Release Results for Q2 2024 and Hold Webcast
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday,
Street Calls of the Week: Stifel Initiates on Tesla; Downgrade for Alphabet
Qiagen Upgraded at Wolfe on Valuation Discount
Qiagen Raised to Outperform From Peer Perform by Wolfe Research
Qiagen Raised to Outperform From Peer Perform by Wolfe Research
Wolfe Research Upgrades Qiagen to Outperform, Announces $50 Price Target
Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:QGEN) from Peer Perform to Outperform and announces $50 price target.
Wolfe Research Upgrades Qiagen NV(QGEN.US) to Buy Rating, Announces Target Price $50
Wolfe Research analyst Doug Schenkel upgrades $Qiagen NV(QGEN.US)$ to a buy rating, and sets the target price at $50.According to TipRanks data, the analyst has a success rate of 65.6% and a total ave
FDA Approves Bristol Myers Squibb's Combination Therapy For Colorectal Cancer Patients With Certain Type Of Gene Mutation
Friday, the FDA granted accelerated approval to Bristol Myers Squibb & Co's (NYSE:BMY) Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C
CORRECTION : JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $54 -Analyst Name Updated (Article Originally Published on 18th June)
CORRECTION : JP Morgan analyst Casey Woodring maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54 -Analyst Name Updated (Article Originally Published on 18th Jun
Qiagen on Pace for Largest Percent Decrease Since October 2022 -- Data Talk
QIAGEN NV (QGEN) is currently at $41.82, down $1.93 or 4.4% --Would be lowest close since April 26, 2024, when it closed at $41.65 --On pace for largest percent decrease since Oct. 19, 2022, when it
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell sharply in today's pre-market trading
J.P. Morgan Maintains Qiagen NV(QGEN.US) With Buy Rating, Raises Target Price to $54
J.P. Morgan analyst Casey Woodring maintains $Qiagen NV(QGEN.US)$ with a buy rating, and adjusts the target price from $52 to $54.According to TipRanks data, the analyst has a success rate of 40.5% an
Express News | Qiagen NV : UBS Raises Target Price to $46 From $44
Qiagen Is Maintained at Overweight by JP Morgan
Qiagen Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Qiagen, Raises Price Target to $54
JP Morgan analyst Tycho Peterson maintains Qiagen (NYSE:QGEN) with a Overweight and raises the price target from $52 to $54.
Qiagen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 22.13% JP Morgan $52 → $54 Maintains Overweight 05/01/2024 1.78% Stifel $55 → $45 Maintains Hol
A Quick Look at Today's Ratings for Qiagen NV(QGEN.US), With a Forecast Between $49 to $54
On Jun 18, major Wall Street analysts update their ratings for $Qiagen NV(QGEN.US)$, with price targets ranging from $49 to $54.J.P. Morgan analyst Casey Woodring maintains with a buy rating, and adju
Express News | Qiagen NV : JP Morgan Raises Target Price to $54 From $52
Qiagen Unveils Plan For $1B Shareholder Returns, Major Product Launches
On Monday, Qiagen NV (NYSE:QGEN) announced at its Capital Markets Day a comprehensive strategy aimed at delivering solid and profitable growth through 2028.The company targets a 7% compound annual sal